The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Understanding And Controlling Remodelling In Pulmonary Fibrosis And Asthma
Funder
National Health and Medical Research Council
Funding Amount
$431,839.00
Summary
The development of scar tissue is a normal response to tissue injury. When airway and lung tissue is injured by exposure to irritants, scarring greatly diminishes the function of the lung to allow transfer of oxygen to the tissue. In severe disease, the scarring may be fatal. We discovered that two factors involved in formation of scar tissue neutralise each other's effects. We are examining this interaction in human lung to develop new treatments for scarring-related lung diseases.
Dr Reid is a respiratory physician determining the relationships between bacterial pathogen behaviour and the host immune response in Cystic Fibrosis. The aim of his research is to use observations made in the clinical setting to develop novel therapeutics and identification of biomarkers that will be employed to pre-empt and better treat clinical disease with the ultimate aim of improving length and quality of life.
Novel Candidate Genes, Lung Function And Allergic Airways Disease
Funder
National Health and Medical Research Council
Funding Amount
$581,892.00
Summary
We propose to study airway remodelling (structural changes to the airway) and in asthma using human samples and rodent models of asthma. We are particularly interested in investigating the role of trefoil peptide 2 and relaxin, two genes identified as determining lung function. To do this we need to understand the mechanisms of airway remodelling and its impact on disease severity in the patient. A strength of this study is availability of samples from a large study of human asthma.
Novel Methods For The Early Identification Of Progressive Disease In Idiopathic Pulmonary Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$676,685.00
Summary
Idiopathic Pulmonary Fibrosis (IPF) is a severe and progressive lung disease with no proven treatment. IPF causes persistent scarring in the lungs that reduces the lungs ability to transfer oxygen into the bloodstream. The rate at which the disease progresses is highly variable, some patients remain stable while others deteriorate rapidly. This research will look for indicators that predict the rate of disease progression. Understanding this will assist doctors to improve the management of IPF.
Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specificall ....Airway fibrosis or scaring causes significant morbidity in both chronic obstructive pulmonary disease (COPD) and asthma . These diseases affect 10-15% of the population, and cost the health system $1.15 billion per year. Airway fibrosis is not decreased by the current therapeutics used to treat COPD and asthma, and as such there is a pressing need to develop therapeutics to specifically treat airway fibrosis. Dr Brian Oliver has partnered with Pharmaxis to develop new therapeutics to specifically treat fibrosisRead moreRead less
Targeting IL-33 In Chronic Obstructive Pulmonary Disease (COPD), Chronic Asthma And Idiopathic Pulmonary Fibrosis (IPF)
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Lung diseases (emphysema, severe asthma & pulmonary fibrosis) are major burdens on Australian community and economy. Airway wounding is a key feature of all these diseases. Patients experience severe breathlessness seriously impacting quality of life and frequently leading to death. We will assess the potential of a new target (IL-33), & therapy (anti-IL-33) in suppressing wounding in experimental models and human tissues. This may lead to a new treatment to reverse and/or prevent lung diseases.
Does The Pattern Of Ventilation Distribution Predict Airway Hyperresponsiveness?
Funder
National Health and Medical Research Council
Funding Amount
$256,973.00
Summary
The tendency for airways to narrow too easily when stimulated is called airway hyperresponsiveness (AHR). AHR is an important feature of asthma, but it also occurs in other diseases, such as chronic obstructive pulmonary disease (COPD) - an airway disease caused by smoking, and cystic fibrosis. People who have AHR have more severe respiratory disease, regardless of which disease they have, and are more likely to develop poor lung function in old age and to be hospitalised or die from their disea ....The tendency for airways to narrow too easily when stimulated is called airway hyperresponsiveness (AHR). AHR is an important feature of asthma, but it also occurs in other diseases, such as chronic obstructive pulmonary disease (COPD) - an airway disease caused by smoking, and cystic fibrosis. People who have AHR have more severe respiratory disease, regardless of which disease they have, and are more likely to develop poor lung function in old age and to be hospitalised or die from their disease. If we can understand the causes of AHR we will have a better understanding of why some people with respiratory disease have poor outcomes. We have recently discovered that, in asthma, there is a very close relationship between AHR and the uneven distribution of air within the lungs. We believe that structural changes in the airways that cause this uneven distribution make the airways prone to AHR. This raises the possibility that factors that cause uneven ventilation in other respiratory diseases might also predispose the airways to AHR. If this is true, it suggests that there is a single physiological basis for AHR in a range of different diseases, and would allow us to focus research more closely on the causes of uneven ventilation. In this project we will measure the relationship between AHR and uneven ventilation in people with asthma, COPD or cystic fibrosis. The study is important because older people with asthma, particularly those with permanently narrowed airways, are likely to have more structural changes in their airways than young asthmatics, whereas people with COPD and cystic fibrosis have a different pattern of both structural changes and airway inflammation from that in asthma. The study will tell us whether there is a consistent relationship between AHR and uneven ventilation. If so, this would be extremely strong evidence that the factors that cause uneven ventilation contribute to AHR, and will point the way to studies of new treatments.Read moreRead less
Understanding The Mechanisms Underlying Airway Remodelling
Funder
National Health and Medical Research Council
Funding Amount
$451,716.00
Summary
Changes in the structure of the lung contribute to the development of disease, but are not responsive to our current therapies. I have found two key structural proteins that are altered in asthma. This research will characterise the regulation and role of these proteins in the disease process. In addition, it will determine if these proteins also contribute to the development of other serious fibrotic diseases, for which there are no current treatments.